
    
      The main purpose of this study is to assess the efficacy of TAS-205 in patients with Duchenne
      muscular dystrophy (DMD) compared with placebo as measured by the mean change from baseline
      to 52 weeks in the time to rise from the floorï¼Ž Following completion of the treatment period,
      patients may elect to continue in open-label extension study.
    
  